
Datwyler accelerates its profitable growth.
Despite the ongoing uncertainty caused by the pandemic, Datwyler has increased its forecasts for the year as a whole for revenue and EBIT margin to over CHF 1’150 million and above 16%, respectively.
Despite the ongoing uncertainty caused by the pandemic, Datwyler has increased its forecasts for the year as a whole for revenue and EBIT margin to over CHF 1’150 million and above 16%, respectively.
The company will also showcase NeoFlex™ plungers and DuraCoat™ combiseals, which enable drug developers to protect the integrity of injectables throughout development to distribution.
From August 30-31, Datwyler will be hosting a 2-day virtual training course with the Parenteral Drug Association (PDA) on Characteristics of Pharmaceutical Elastomers and Aluminum Seals in Parenteral Packaging Systems.
We are thrilled to announce the return of our tradeshows in North America.
For years, Datwyler has been supporting the inhabitants of the surrounding villages through various community projects, thereby having a positive influence on the local environs.
As a founding member of the Alliance to Zero Datwyler aims net zero emissions across the pharmaceutical supply chain.